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Aims: Evaluate the efﬁcacy and tolerability of ITCA 650 in subjects with type 2 diabetes treated for up to
48 weeks.
Methods: This was a 24-week extension to a randomized, 24-week, open-label, phase 2 study in subjects
with type 2 diabetes inadequately controlled with metformin. Subjects received ITCA 650 mg (20, 40, 60 or
80 μg/day). Mean changes for HbA1c, weight, and fasting plasma glucose (FPG) were evaluated.
Results:Mean changes in HbA1c from baseline to week 48 ranged from−0.85% to−1.51%. At week 48,≥64%
of subjects with an HbA1c ≤7% at week 24 maintained an HbA1c ≤7%. The incidence of adverse events (AEs)
was dose-related and ranged from 13.3% with 20 μg/day to 37.5% with 80 μg/day. Most AEs were mild and
transient; the incidence of nausea declined from 12.9% to 9.5% over the 24-week extension. One subject on
ITCA 650 80 μg/day experienced mild intermittent vomiting. Three (3.5%) subjects experienced severe AEs,
but none were considered related to study drug.
Conclusion: Signiﬁcant changes in HbA1c, body weight, and FPG attained with ITCA 650weremaintained to 48
weeks. The incidence of AEs was lower in the 24-week extension than in the initial 24-week treatment phase.
Published by Elsevier Inc.Open access under CC BY-NC-ND license.  1. Introduction
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patients with type 2 diabetes is to achieve control of both glycemia as
well as other co-morbidities during long-term, usually lifetime,
antidiabetic treatment.
Glucagon-like peptide-1 (GLP-1) receptor agonists are widely
effective for achieving glycemic control and weight reduction in
patients with type 2 diabetes (Fakhoury, Lereun, & Wright, 2010;
Shyangdan, Royle, Clar, Sharma, & Waugh, 2010). Long-term
studies with liraglutide and twice daily and once weekly
formulations of exenatide have shown that glycemic control and
weight loss are maintained and that the incidence of new onset
side effects is low after up to 3 years of therapy (Astrup, Carraro,
Finer, et al., 2012; Buysschaert, Preumont, Oriot, et al., 2010;
Diamant, Van Gaal, Stranks, et al., 2012; Gallwitz, Guzman, Dotta,
et al., 2012; Macconell, Pencek, Li, Maggs, & Porter, 2013).
However, currently available products require subcutaneous (SC)
injection either once (liraglutide) or twice daily (exenatide BID) or
once weekly (exenatide), which may negatively impact patient
tolerability, adherence, and persistence during long-term treat-
ment. Studies show that poor adherence to antidiabetic medication
results in poor clinical outcomes and increased healthcare costs
(Breitscheidel, Stamenitis, Dippel, & Schöffski, 2010; Jha, Aubert,
Yao, Teagarden, & Epstein, 2012).
ITCA 650 is a miniature osmotic pump system that is designed to
deliver zero-order, continuous subcutaneous (SC) release of exena-
tide at a precise predetermined rate for up to 12 months with a single
placement (Rohloff et al., 2008; Yang, Negulescu, D’vaz, et al., 2009). A
sterile, single use tool is utilized to place the small match stick sized
sterile product subcutaneously in the abdominal region during a short
(~5 min) aseptic ofﬁce procedure performed by a physician, physi-
cian's assistant or other licensed healthcare provider (Rohloff et al.,
2008). At the end of the dosing period, the skin is prepared and the
product is removed through a very small (~5 mm) incision, and a new
product can be placed in the same location. Because similar
procedures for other non-biodegradable drug delivery systems are
reimbursed by payers in the United States under established Common
Procedural Terminology (CPT) codes, it is expected that the placement
and removal procedures for ITCA 650 also will be reimbursed.
ITCA 650 has several potential advantages over other GLP-1 RAs for
the treatment of type 2 diabetes including rapid attainment and
maintenance of consistent therapeutic drug concentrations without
the need for frequent self-injection, more constant and predictable
drug levels, and almost certain 100% adherence to therapy (Henry,
Logan, Alessi, & Baron, 2013). The pharmacological effect of exenatide
ends within 24 h following removal of ITCA 650 allowing for rapid
termination of drug effect if needed. Increased adherence with once or
twice yearly dosing with ITCA 650 has the potential to improve
glycemic control and long-term outcomes from type 2 diabetes, which
may translate into lower healthcare costs (Jha et al., 2012).
In a randomized, 24-week, open-label, phase 2 study in subjects
with type 2 diabetes inadequately controlled with metformin,
subjects initially were randomized to 20 or 40 μg/day of ITCA 650 or
exenatide BID injection (5 μg BID for 4 weeks titrated to 10 μg BID for
8 weeks) for 12 weeks to determine the appropriate initial dose of
ITCA 650. Subjects thenwere re-randomized to 20, 40, 60 or 80 μg/day
of ITCA 650 for a 12-week dose ranging evaluation (Henry et al.,
2013). All doses of ITCA 650 signiﬁcantly reduced HbA1c and body
weight at 12 and 24 weeks and were well tolerated. This report
presents results from an optional 24-week extension phase designed
to evaluate the long-term effects of ITCA 650 on glycemic control,
body weight, and tolerability.
2. Methods
The study was approved by an appropriately constituted institu-
tional review board and conducted in accordancewith the Declarationof Helsinki and ICH guidelines for Good Clinical Practice. All subjects
gave written informed consent. This study was registered at
ClinicalTrials.gov: NCT00943917.
2.1. Study Design
This was a 24-week open-label extension phase of a randomized,
two-stage, 24-week, phase 2 study (Fig. 1) that was conducted at 41
centers in the United States (Henry, Rosenstock, et al., 2013). The
results from the randomized, 24-week core study were previously
published (Henry, Rosenstock, et al., 2013). In summary, all doses of
ITCA 650 resulted in clinically and statistically signiﬁcant reductions
in HbA1c at 24 weeks. The 60 μg/day dose was selected as the
maintenance dose to be taken into phase 3 and achieved HbA1c goal
≤7% in 67.6%, 63.0%, and 61.1% of subjects with baseline HbA1c levels
N7.0%, ≥7.5%, and ≥8.0%, respectively. Subjects who completed
the 24-week core study were offered the option of continuing with a
24-week treatment continuation period on the same dose of ITCA
650 (20, 40, 60 or 80 μg/day) that they were taking at week 24.
Subcutaneous placement of the assigned dose of ITCA 650 was
performed by site personnel at the beginning of the open-label
continuation period (see Data Supplement). At the end of the extension
all subjects returned to the clinical study site 4 weeks after the removal
of ITCA 650 for a post-treatment follow-up visit.
2.2. Subject Selection
The inclusion and exclusion criteria were previously described in
detail (Henry, Rosenstock, et al., 2013). In brief, men and women age
from 18 to 70 years of age with a diagnosis of type 2 diabetes mellitus
for at least 6 months and on a stable dose of metformin for at least 3
months prior to study entry were eligible if their HbA1c was between
7% and 10% inclusive, fasting plasma glucose (FPG) was less than
240 mg/dL, body mass index (BMI) was 40 kg/m2 or less, and they
had a stable body weight.
2.3. Study Assessments
HbA1c, FPG, serum amylase, and lipase levels were measured at
weeks 36 and 48 and FPG was also measured at follow up. Insulin,
proinsulin, C-peptide, glucagon, and calcitonin levels as well as lipid
Table 1
Baseline demographic and clinical characteristics.
ITCA Dose
20 μg/day
(n = 15)
40 μg/day
(n = 28)
60 μg/day
(n = 27)
80 μg/day
(n = 16)
Age (years)a 55.6 ± 7.7 54.7 ± 9.4 52.9 ± 9.2 55.9 ± 7.9
Female (%) 9 (60.0) 19 (67.9) 11 (40.7) 7 (43.8)
Race, (%)
White 13 (86.7) 22 (78.6) 26 (96.3) 13 (81.3)
African American 2 (13.3) 6 (21.4) 1 (3.7) 2 (12.5)
Asian 0 0 0 1 (1.2)
Duration of
diabetes (years)a
7.0 ± 5.8 6.0 ± 4.2 5.3 ± 4.1 11.2 ± 13.2
Metformin dose at
screening (mg)a
1367 ± 611 1527 ± 605 1275 ± 546 1566 ± 634
Body weight, (kg)a 100.9 ± 13.4 90.8 ± 14.2 93.0 ± 15.1 92.4 ± 20.4
BMI ≥30 kg/m2,
n (%)
13 (86.7) 20 (71.4) 16 (59.3) 8 (50.0)
HbA1c (%)a 7.91 ± 0.82 7.88 ± 0.76 8.22 ± 0.91 7.98 ± 0.94
FPG (mg/dL)a 150.9 ± 24.6 149.7 ± 35.3 156.3 ± 33.0 167.5 ± 75.8
BMI = body mass index; FPG = fasting plasma glucose; HbA1c = glycated
hemoglobin; SD = standard deviation.
a Mean ± standard deviation.
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events, clinical laboratory measurements (chemistry, hematology,
and urinalysis), 12-lead electrocardiogram (ECG), vital signs, and
physical examinations. All laboratory and safety assessments were
performed at screening and baseline visits for the 24-week study and
throughout the extension at weeks 36, 48, and follow up. A physical
examination including vital signs and body weight was obtained at
weeks 36, 48, and follow up. Anti-exenatide antibodies were
measured at week 48 and the 4-week post study follow up.
2.4. Statistical Analysis
The primary efﬁcacy endpoints were change from baseline for
HbA1c, FPG, and body weight. Changes or percent changes from
baseline were analyzed with an analysis of covariance (ANCOVA)
model with treatment as a factor and baseline as the covariate.
Pairwise comparisons were reported using least square (LS) means
and standard errors (SE) for each treatment, and LS means, SE, 95%
conﬁdence intervals, and p-values. The proportion of subjects reach-
ing HbA1c levels at below 7% was reported. For adverse event data,
descriptive statistics were reported.
The safety population was deﬁned as all randomized subjects who
received at least 1 dose of study medication and who received study
medication in the extension phase. The intent to treat (ITT)
population was deﬁned as all subjects who entered the extension
and had a post baseline assessment.Table 2
Mean and mean change from baseline to week 48 for HbA1c, FPG, and body weight.
ITCA Dose
20 μg/day (n = 15) 40 μg/day
HbA1c, %
Mean ± SD endpoint 6.77 ± 0.63 7.03 ± 1.2
LS Mean ± SE −1.20 ± 0.26 −0.93 ± 0
P-valuea b0.0001 b0.0001
FPG (mg/dL)
Mean ± SD endpoint 128.3 ± 41.6 136.0 ± 6
LS Mean ± SE −24.5 ± 12.1 −16.1 ± 8
P-valuea 0.045 0.072
Body weight (kg)
Mean ± SD endpoint 98.7 ± 13.8 86.5 ± 16
LS Mean ± SE −2.4 ± 1.5 −4.2 ± 1.
P-valuea 0.107 b0.001
a Analysis of covariance model with treatment as a factor and baseline value as a covaria3. Results
Eighty-six subjects (83.5% of eligible subjects) chose to enter the
24-week extension, and 73 completed the entire 48-week study.
Three study centers from the original 44 centers that enrolled subjects
in the 24-week study did not participate in the extension (16.9% of
eligible subjects). Subjects were grouped by treatment assignments
according to the dose (20, 40, 60, or 80 μg/day of ITCA 650) that they
received during the maintenance and extension phases, which
represented 36 to 48 weeks of treatment at each dose. Thirteen
subjects discontinued for the following reasons: withdrawn consent
(4), hypoglycemia (1), elevated HbA1c (1), adverse event (5), and
other (2). Baseline demographics and clinical characteristics were
generally comparable between groups during the extension phase,
except for a higher proportion of females in the 20 and 40 μg groups
and a longer duration of diabetes in the 80 μg group (Table 1).
Baseline characteristics and results at week 24 for the extension
population were comparable to those of the overall population of
subjects who entered the randomized, open-label phase.
3.1. Effects on Glycemic Control and Body Weight
Themean change in HbA1c from baseline to week 24 (beginning of
extension phase) was−0.98%,−0.87%,−1.56%, and−1.38% for the
20, 40, 60, and 80 μg/day groups, respectively with the 60 μg/day dose
achieving HbA1c goal ≤7% in 67.6%, 63.0%, and 61.1% of subjects with
baseline HbA1c levels N7.0%, ≥7.5%, and ≥8.0%, respectively. For
subjects who entered the 24-week extension phase, the LS mean
change from baseline to week 48 ranged from−0.93% to−1.42% and
was signiﬁcant (p b 0.0001) for all four doses of ITCA 650 (Table 2).
Fromweek 24 to week 48, mean change in HbA1c was non-signiﬁcant
and ranged from −0.15% to 0.1% across the four treatment groups
indicating that the reduction in HbA1c observed at week 24 was
maintained during the extension phase (Fig. 2a). At week 48, at least
64% of subjects across all treatment groups with an HbA1c level ≤7%
at week 24 maintained an HbA1c level at ≤7%.
The LS mean change from baseline to week 48 for FPG was
signiﬁcant (p b 0.05) in the 20, 60, and 80 μg/day dose groups,
ranging between −24.5 to −28.2 mg/dL. FPG in the 40 μg/day dose
group decreased by 16.1 mg/dL (p = 0.072) (Table 2). The change
achieved by Week 24 was largely maintained at Week 48 (Fig. 2b).
The mean change from baseline to week 48 for body weight was
signiﬁcant (p b 0.05) in the 40, 60, and 80 μg/day ITCA 650 groups
and ranged from−2.4 to−4.2 kg. In the 20 μg/day group, weight loss
was−2.4 kg (p = 0.017). Changes in mean body weight achieved at
week 24 also were maintained at week 48 (Fig. 2c).
Mean changes from baseline to 48 weeks or 24 to 48 weeks for
other pharmacodynamic variables C-peptide, fasting insulin, glucagon
and proinsulin were variable with no consistent dose-related pattern.(n = 28) 60 μg/day (n = 27) 80 μg/day (n = 16)
6 6.70 ± 0.80 6.58 ± 1.23
.19 −1.39 ± 0.19 −1.42 ± 0.25
b0.0001 b0.0001
0.8 129.6 ± 31.2 133.9 ± 71.1
.8 −26.3 ± 9.0 −28.2 ± 11.7
0.004 0.019
.1 90.0 ± 16.3 88.9 ± 22.8
1 −3.0 ± 1.1 −3.4 ± 1.4
0.007 0.019
te.
Fig. 2. Mean (SD) values for HbA1c, FPG, and body weight at baseline and 24 and 48
weeks for subjects who entered the 24-week extension phase (n = 86).
Table 3
Incidence of adverse events occurring in at least 10% of subjects during 24-week
extension.
Number (%) of Subjects
ITCA Dose
20 μg/day
(n = 15)
40 μg/day
(n = 28)
60 μg/day
(n = 27)
80 μg/day
(n = 16)
Any AE 9 (60.0) 15 (53.6) 15 (55.6) 11 (68.6)
Any drug-related AE 2 (13.3) 7 (25.0) 7 (25.9) 6 (37.5)
Severe AE 0 1 (3.6) 1 (3.7) 1 (6.3)
Serious AE 0 1 (3.6) 1 (3.7) 2 (12.5)
Discontinued for AE 0 2 (7.1) 1 (3.7) 2 (12.5)
Arthralgia 2 (13.3) 1 (3.6) 0 0
Diarrhea 1 (6.7) 2 (7.1) 0 0
Headache 1 (6.7) 0 0 2 (12.5)
Hypoglycemia 0 0 0 2 (12.5)
Incision site
complication
1 (6.7) 1 (3.6) 3 (11.1) 1 (6.3)
Incision site
infection
0 0 3 (11.1) 0
Incision site pain 0 1 (3.6) 2 (7.4) 3 (18.8)
Incision site
pruritus
0 1 (3.6) 2 (7.4) 0
Nasopharyngitis 0 3 (10.7) 1 (3.7) 0
Urinary tract
infection
2 (13.3) 3 (10.7) 2 (7.4) 0
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cholesterol, LDL- and HDL-cholesterol, and plasma triglycerides that
were variable across ITCA 650 dose groups.
3.2. Safety and Tolerability
During the extension phase, treatment emergent AEs occurred in
58.1% of subjects and the incidence ranged from 54% to 69% across
dose groups (Table 3). Drug-related AEs occurred in 25.6% of subject
and appeared to be dose-related, ranging from 13.3% with 20 μg/day
to 37.5% with 80 μg/day. The most common AEs experienced by
≥10% of subjects in any treatment group were urinary tract
infection (7 [8.1%]) subjects), incision site complication (6 [7.0%]
subjects), incision site pain (6 [7.0%] subjects), incision site
erythema (4 [4.7%] subjects), and nasopharyngitis (4 [4.7%] sub-
jects). Most side effects were mild and transient; the overall
incidence of nausea declined from 12.9% to 9.5% of all subject over
the 24 week extension, and only one subject experienced vomiting
during this period. Three (3.5%) subjects experienced treatment
emergent AEs that were considered severe but none were
considered related to study drug.
Five subjects discontinued ITCA 650 for treatment-emergent AEs
during the 24-week extension. These AEs included hypoglycemia
(80 μg/day), pyrexia (40 μg/day), incision site pain, erythema, and
infection (60 μg/day). Two subjects were discontinued: one for rectal
cancer and the other for myocardial infarction; both of which were
considered by the Investigator to be unrelated to study treatment. In
total, four subjects experienced serious AEs during the 24-week
extension; labrynthitis, rectal cancer, myocardial infarction, and
subclavian artery stenosis. The subject with myocardial infarction
died during the study. None of these events were considered related
to ITCA 650 treatment.
No clinically meaningful trends or dose-related effects in vital
signs were observed during the extension phase across treatment
groups. No signiﬁcant changes in lipid proﬁles (cholesterol,
triglyceride, LDL- and HDL-cholesterol) were observed from baseline
to Week 48 except for a signiﬁcant (p = 0.0101) increase in HDL
(10.1%, 3.6 mg/dL) with the ITCA 650 80 μg group. Mean changes in
serum calcitonin (−0.51 to 0.18 pg/mL), thyroid stimulating
hormone (−0.20 to 0.19 υIU/L), amylase (−1.1 to −5.3 U/L), and
lipase (−0.2 to−14.1 U/L) were small and no meaningful treatment-
397R.R. Henry et al. / Journal of Diabetes and Its Complications 28 (2014) 393–398related differences were observed. Two subjects in the 20 μg/day group
and 1 in the 60 μg/day group had a serum lipase level N2 times the
upper limit of normal, but these elevations were not accompanied by
clinical symptoms. No subject developed pancreatitis.
The incidence of positive anti-exenatide antibodies was 19.9% at
week 12, 12.9% at week 24 and 2.8% at Week 48. The incidence of high
anti-exenatide titers (N7,500) at week 48 was zero in all groups. No
trend was observed for titers to increase over time from the initial
stage of the study through week 48. Furthermore, no apparent effect
of anti-exenatide antibodies was observed on exenatide plasma
concentrations, pharmacodynamic parameters or serious AEs.
4. Discussion
This report describes the response to treatment with ITCA 650 in
subjects with type 2 diabetes onmetforminmonotherapywho elected
to enter an optional 24-week extension phase of a 24-week,
randomized phase 2 dose ranging trial (Henry, Rosenstock, et al.,
2013). Forty-one of the 44 study centers that enrolled subjects in the
initial 24 week study participated in the extension and 85% of eligible
subjects at those sites elected to continue into the extension phase.
The decision to participate in the extension did not appear to be
inﬂuenced by the presence or absence of nausea during the 24-week
core study or by any concerns related to the minor skin procedure to
place the ITCA 650. During the 24-week extension, treatment with
ITCA 650 was well tolerated and signiﬁcant reductions in HbA1c, FPG,
and body weight that were present at 24 weeks were sustained to 48
weeks with no evidence of a loss of effect. High anti-exenatide
antibody titers were not observed at 48 weeks.
The results from the initial 24-week study and this extension
phase were valuable for the selection of the 60 μg dose as the
maintenance dose to be used in phase 3 clinical studies of ITCA 650
following a 3 month introductory dose of 20 μg/day. The 60 μg was
selected based on the overall reduction in HbA1c, the percent of
patients reaching goal, and the robust reduction seen across the
spectrum of HbA1c, including those patients with a high baseline
HbA1c. In addition, the tolerability proﬁle was better at 60 μg
compared to 80 μg with only a modest incremental increase in
efﬁcacy at the 80 μg/day dose. This extension phase supported both
sustainability of effect and long-term tolerability of ITCA 650. The low
incidence of anti-exenatide antibodies in this trial relative to 32% to
45% incidence reported in other trials of exenatide (Macconell et al.,
2013) could be attributed to the consistent plasma levels of exenatide
achieved with ITCA 650, although comparing antibody data between
studies is problematic. Larger, long-term studies are under way with
ITCA 650 that will provide further evidence about the incidence of
anti-exenatide antibodies.
The limitations of this study include the open-label design with
no active or placebo control group, and the relatively small numbers
of subjects that were included in each treatment group. However,
this study provides valuable information on the maintenance of
effect and the tolerability of ITCA 650 when treatment was extended
to 48 weeks.
The clinical challenges encountered with long-term pharmacolog-
ical treatment of type 2 diabetes include hypoglycemia, weight gain,
and side effects and aversion to self-injection, which often contribute
to poor adherence and persistence with therapy (Bron, Marynchenko,
Yang, Yu, & Wu, 2012; Ha, Oh, Kim, et al., 2012; Nau, 2012; Quilliam,
Simeone, Ozbay, & Kogut, 2011; Williams et al., 2012; Willis, Diago-
Cabezudo, Madec-Hily, & Aslam, 2013). Poor adherence and persis-
tence with antidiabetic therapy are common; a systematic review of
the literature reported that adherence rates to oral drugs ranged from
36% to 93% and for insulin was approximately 60% (Cramer, 2004),
and a recent report found discontinuation rates N80% with GLP-1 RAs
at 12 months (Koro et al., 2013). An evaluation of persistence with
injectable antidiabetic agents, which included insulin and exenatidefound that only 28.7% of patients persisted with therapy to 1 year
(Cooke, Lee, Tong, & Haines, 2010). The consequences of poor
adherence include inadequate glycemic control, increased morbidity
and mortality, and markedly increased healthcare costs (Ho, Rumsfeld,
Masoudi, et al., 2006; Raum, Krämer, Rüter, et al., 2012; Salas, Hughes,
Zuluaga, Vardeva, & Lebmeier, 2009). Many interventions have been
studied and recommended to increase medication adherence, but most
require extensive and continuous use of costly healthcare resources,
and the beneﬁcial effects on adherence are temporary (Egginton,
Ridgeway, Shah, et al., 2012). These concerns about poor compliance
and adherence to exenatide are abrogated by the use of ITCA 650.
The results from this 24-week extension of a dose ranging phase 2
study demonstrate signiﬁcant dose-related effects on HbA1c, FPG,
and body weight that were sustained to 48 weeks in subjects who
chose to continue beyond the initial 24-week randomized phase.
These effects were accompanied by lower rates of nausea and other
AEs commonly associated with GLP-1 RA. ITCA 650 offers potential
advantages for the long-term treatment of diabetes secondary to an
improved tolerability proﬁle and virtually 100% adherence with
therapy. In addition, ITCA 650 provides convenience and ease of use
for both patients and health care professionals with a relatively
simple placement and removal procedure conducted in an ofﬁce
environment. The phase 3 clinical development program for ITCA 650
will explore efﬁcacy, safety, and tolerability in a wide cross section of
subjects with type 2 diabetes.
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